AI Summary
We reviewed 35 live results for amgevita (adalimumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Pharmaceuticals.
AI Summary
We reviewed 35 live results for amgevita (adalimumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Pharmaceuticals.
Comparison Table
Source: Amgen (Thailand) Limited
Description
Amgevita is a biosimilar to Humira, containing the active substance adalimumab. It is used as a biologic therapy for inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Available in Thailand as a solution for injection in 20 mg/0.4 ml and 40 mg/0.8 ml pre-filled syringes or autoinjectors, it is classified as a Special Controlled Drug that requires professional medical supervision for prescription and dispensing.
Best for
rheumatoid arthritis patients, biosimilar drug preference, chronic inflammation management and specialized biologic therapy
Rating
Source: Amgen Inc.
Description
Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes.
Best for
international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients
Rating
Source: Amgen Biotechnology Singapore Pte Ltd
Description
Amgevita is a biosimilar to Humira (adalimumab) registered in Singapore for the treatment of various inflammatory conditions, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. As an anti-inflammatory biologic, it provides a high-quality, cost-effective alternative for patients managing chronic autoimmune diseases.
Best for
rheumatoid arthritis patients, plaque psoriasis treatment and cost-effective biologic access
Rating
| Compare | Amgevita (adalimumab-atto) | Amgevita (adalimumab) | Amgevita |
|---|---|---|---|
| Source | Amgen (Thailand) Limited | Amgen Inc. | Amgen Biotechnology Singapore Pte Ltd |
| Description | Amgevita is a biosimilar to Humira, containing the active substance adalimumab. It is used as a biologic therapy for inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Available in Thailand as a solution for injection in 20 mg/0.4 ml and 40 mg/0.8 ml pre-filled syringes or autoinjectors, it is classified as a Special Controlled Drug that requires professional medical supervision for prescription and dispensing. | Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes. | Amgevita is a biosimilar to Humira (adalimumab) registered in Singapore for the treatment of various inflammatory conditions, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. As an anti-inflammatory biologic, it provides a high-quality, cost-effective alternative for patients managing chronic autoimmune diseases. |
| Best for | rheumatoid arthritis patients, biosimilar drug preference, chronic inflammation management and specialized biologic therapy | international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients | rheumatoid arthritis patients, plaque psoriasis treatment and cost-effective biologic access |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Amgevita (adalimumab-atto) from Amgen (Thailand) Limited."
I picked this because Amgevita is a reputable biosimilar offering from Amgen, providing a more accessible treatment option for patients requiring adalimumab with proven safety and efficacy profiles.
Share this search
Related Finds